10-Q: QHSLab Reports Revenue Growth Amidst Operating Losses

QHSLab, Inc. filed its Q2 2026 10-Q, showing increased revenues driven by its Integrated Service Program, but continued operating losses and a going concern warning.

Summary

• QHSLab, Inc. reported revenues of $847,490 for the three months ended June 30, 2026, an increase from $605,446 in the prior year period.
• For the six months ended June 30, 2026, revenues were $1,576,175, up from $1,250,865 in the same period last year.
• The company experienced an operating loss of $49,135 for the six months ended June 30, 2026, compared to a loss of $513 in the prior year period.
• Despite revenue growth, the company continues to face challenges related to its ability to continue as a going concern due to its history of losses and current cash burn.
• The company's disclosure controls and procedures were found to be ineffective due to a lack of adequate personnel with financial reporting experience.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously optimistic score, reflecting revenue growth but also persistent operating losses and going concern uncertainties.

Positives

• Revenue increased by 26% for the six months ended June 30, 2026, compared to the same period in 2025, reaching $1,576,175.
• Integrated Service Program (ISP) revenue saw a significant increase of 103.2% in the first half of 2026, contributing $865,900.
• Gross margin improved to 69.6% for the three months ended June 30, 2026, up from 65.9% in the prior year period.
• Interest expense decreased significantly due to the conversion and settlement of loans.
• The company achieved profitability in the current quarter following a period of operating losses, though this is recent.

Negatives

• The company reported an operating loss of $49,135 for the six months ended June 30, 2026, an increase from the $513 loss in the prior year period.
• Cash and cash equivalents decreased from $636,157 at December 31, 2025, to $317,392 at June 30, 2026, due to operational use and debt repayment.
• The company has an accumulated deficit of $3,969,427 as of June 30, 2026.
• Disclosure controls and procedures were found to be ineffective due to a lack of adequate personnel with financial reporting experience.

Risks

• The company's history of losses and current cash burn raise substantial doubt about its ability to continue as a going concern.
• Access to future funding may not be available on commercially reasonable terms, if at all.
• The company has net operating loss carryforwards of $3,969,427 which begin to expire in 2027, and their utilization may be limited by ownership change rules.
• The effectiveness of disclosure controls and procedures was found to be lacking due to insufficient personnel with financial reporting experience.

Future Outlook

Management believes its current cash position, anticipated collections of accounts receivable, and expected cash generated from future operations will provide sufficient liquidity for the next twelve months. However, due to the recent return to profitability, there is no assurance that future operating results and cash flows will be sustained. The company expects to continue making disciplined investments in personnel, technology, and commercialization initiatives to support long-term growth, which may increase operating expenses.

Management Comments

• Management believes continued growth in recurring revenue improves the predictability of future operating results, supports expansion of gross margins, and enhances long-term shareholder value.
• Management believes these investments position the Company for continued expansion of its physician network and recurring revenue base.
• Management believes our current cash position, anticipated collections of outstanding accounts receivable, and expected cash generated from future operations will provide sufficient liquidity to fund current operating requirements.
• Management will continue to evaluate opportunities to strengthen liquidity and capital resources as it executes its long-term growth strategy.
• Management has identified corrective actions for the weakness in internal controls and will periodically reevaluate our ability to add personnel and implement improved review procedures as they can be supported by the growth in our business.

Industry Context

StockSavvy.ai notes that QHSLab operates in the value-based healthcare and digital therapeutics space, an area seeing increased adoption driven by regulatory shifts and insurer recognition of AI-enabled digital medicine technologies for chronic care management. The company's focus on providing tools for primary care physicians to increase revenue through reimbursable procedures aligns with industry trends towards decentralized and patient-centric care models.

Comparison to Industry Standards

• The company's gross margin of 69.6% for the quarter is strong, but the overall operating loss and going concern warning highlight the challenges many early-stage healthcare technology companies face in achieving sustainable profitability.
• The increase in sales and marketing expenses as a percentage of revenue, while necessary for growth, needs to be monitored against industry benchmarks for customer acquisition cost (CAC) in the SaaS healthcare sector.
• The company's reliance on Integrated Service Programs (ISP) for revenue growth is a positive trend, as recurring revenue models are generally favored by investors and offer greater predictability compared to one-time product sales.

Corporate Governance

Legal Proceedings

• There are no pending or threatened legal proceedings as of June 30, 2026.

Related Party Transactions

• Amounts due to related parties consist of cash advances received from the Company's principal shareholder.
• A portion of these advances has been converted into a loan to the principal shareholder at 10% per annum, maturing March 31, 2027.
• As of June 30, 2026, $95,548 is due to related parties, including a $90,000 loan and accrued interest.
• The Company's CEO and principal shareholder is also a shareholder of MedScience and receives compensation for services provided to MedScience.

Stakeholder Impact

• Shareholders may experience dilution if additional equity is issued to fund operations.
• The going concern warning indicates potential risks to the company's long-term viability, impacting shareholder value.
• Employees may be affected by the company's financial performance and the need for cost management.
• Customers (physicians) may benefit from the company's tools that increase their practice revenue, but are also subject to the company's ongoing operational stability.

Next Steps

• Continue to upgrade QHSLab software to increase product sales.
• Introduce additional point of care diagnostics and treatments, and digital medicine programs.
• Focus on sustaining profitable operations and positive cash flows.
• Strengthen liquidity and capital resources.
• Implement corrective actions for ineffective disclosure controls and procedures.

Key Dates

Recommendation

The company shows promising revenue growth, particularly in its recurring revenue ISP segment, and has recently achieved profitability. However, the persistent operating losses, significant accumulated deficit, and the explicit going concern warning due to a history of losses and cash burn necessitate a cautious approach. The ineffective disclosure controls also add a layer of risk. While there are positive signs, the uncertainties outweigh the immediate potential for significant upside, making 'hold' the most prudent recommendation until sustained profitability and improved financial stability are demonstrated.

Keywords

QHSLab, 10-Q, Healthcare Technology, SaaS, Integrated Service Program, Allergy Diagnostics, Chronic Disease Management, Financial Results